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Background: Tangier disease (TD) is a rare autosomal recessive disorder, resulting from mutations in the ATP
binding cassette transporter (ABCA1) gene. The deficiency of ABCA1 protein impairs high density lipoprotein (HDL)
synthesis and cholesterol esters trafficking.
Case Report: A 58 year-old female, presenting with complex clinical signs (splenomegaly, dysarthria, dysphagia,
ataxia, tongue enlargement, prurigo nodularis, legs lymphedema, pancytopenia and bone marrow foam cells),
was misdiagnosed as Niemann-Pick C (NPC) and treated with miglustat (300 mg/day), normalizing neurological
symptoms and improving skin lesions and legs lymphedema. Subsequently filipin-staining and molecular analysis
for NPC genes were negative. Lipid profiling showed severe deficiency of HDL, 2 mg/dl (n.v. 45-65) and apoAI,
5.19 mg/dl (n.v. 110-170), suggesting TD as a probable diagnosis. Molecular analysis of ABCA1 gene showed the
presence of a novel homozygous deletion (c.4464-486_4698 + 382 Del). Miglustat treatment was then interrupted
with worsening of some neurological signs (memory defects, slowing of thought processes) and skin lesions.
Treatment was restarted after 7 months with neurological normalization and improvement of skin involvement.
Conclusions: These results suggest miglustat as a possible therapeutic approach in this untreatable disease. The
mechanisms by which miglustat ameliorates at least some clinical manifestations of TD needs to be further
investigated.
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Tangier disease (TD) (OMIM #205400) is a rare auto-
somal recessive disorder, resulting from mutations in the
ATP binding cassette transporter (ABCA1) gene, mapped
to chromosome 9q22-q31. The ABCA1 gene encodes a
multiple trans-membrane domain protein (ABCA1) in-
volved in the efflux of free cholesterol from peripheral
cells to Apolipoprotein A-I (ApoAI) generating nascent
high-density lipoprotein (HDL). As a result of the ABCA1
defect, patients present with a characteristic severe defi-
ciency or absence of HDL in the plasma, rapid catabolism
of ApoAI and an accumulation of cholesterol esters
in macrophages and other reticuloendothelial cells in
multiple tissues [1,2]. Biochemically, the disease is there-
fore characterized by very low plasma levels of HDL* Correspondence: bembi.bruno@aoud.sanita.fvg.it
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unless otherwise stated.and ApoAI, low total cholesterol and normal or high
levels of triglycerides. Classical clinical symptoms include
hyperplastic orange tonsils, polyneuropathy, hepatosple-
nomegaly, enlarged lymph nodes, corneal clouding and
premature atherosclerosis. Nevertheless, several atypical
phenotypic presentations have also been described that in-
clude asymptomatic milder phenotypes, forms with early
cardiac involvement and central nervous system presenta-
tion [3-5]. To date, there is no specific treatment for TD.
At the cellular level, several studies have suggested a
homeostatic link between ABCA1 function and NPC1/
NPC2, the two proteins involved in the transport of chol-
esterol and other lipids from late endosomes/lysosomes to
other cellular compartments, including the endoplasmic
reticulum [6,7]. The deficit of either NPC1 or NPC2
causes Niemann Pick C (NPC) disease (OMIM #257220,
OMIM #607625), a rare autosomal recessive disorder
characterized by the accumulation of unesterified choles-
terol and other lipids within the late endocytic system oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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NPC1 disease fibroblasts. This translates into reduced
HDL particle formation, providing a mechanism for the
reduced plasma HDL cholesterol seen in the majority of
NPC patients [6,9]. Clinically, NPC is characterized by
progressive neurological deterioration and hepatospleno-
megaly, with varying age at onset and ensuing course.
While cholesterol is the main lipid accumulated in periph-
eral tissues in NPC disease, glycosphingolipids (GSL) are
the major species that accumulate in the central nervous
system [8]. Based on these findings, miglustat, an imino
sugar drug that inhibits glucosylceramide synthase, the en-
zyme which catalyses the first step in GSL biosynthesis,
has been evaluated for the treatment of neurological man-
ifestations of NPC disease. Its efficacy was demonstrated
first in animal models [10] and then in an international
randomized clinical trial and in long-term extension stu-
dies [11-13]. Subsequently, miglustat was approved for the
treatment of NPC in European Union countries, as well
as most countries worldwide (e.g. Australia, Argentina,
Canada, Russia).
In this manuscript we report the clinical features
and the follow up of a patient with an atypical form
of Tangier disease, who was initially misdiagnosed as
NPC disease and treated with miglustat resulting in
clinical benefit.
Methods
Filipin staining and NPC1-NPC2 molecular analysis
The filipin test for NPC disease was performed on cul-
tured skin fibroblasts using the method described by
Blanchette-Mackie et al. [14].
Molecular analysis of NPC1, NPC2 was performed by
PCR amplification of the exonic and intronic flanking
regions, as previously described [15].
Cell cholesterol efflux
Skin fibroblasts from patients with TD and healthy con-
trols were used for the assay of ABCA1-mediated chol-
esterol efflux. Cell monolayers were incubated for 24 h
in medium containing [1,2-3H]-cholesterol (2 μCi ml)
and 1% fetal bovine serum. Following the 24 h labeling
period, cells were washed and incubated overnight in
media containing 0.2% bovine serum albumin, in the
presence or absence of 9-cis-retinoic acid (5 μmol/l) and
22-hydroxycholesterol (10 μmol/l) to induce ABCA1 ex-
pression. [1,2-3H]-cholesterol-labeled monolayers were
incubated for 6 h (efflux time) in the presence and in
the absence of human Apo A-I (25 μg ml) as free choles-
terol acceptor. Cholesterol efflux was quantified by mea-
suring the radioactivity of the incubation medium after
the removal of floating cells by centrifugation, using a time
zero (To) set of cells to calculate total [3H]-cholesterol
content in the monolayer. Fractional efflux was calculatedas cpm [3H] in the medium ⁄ [3H] at T0 × 100. All the ef-
flux assays were performed in triplicate [16].
RNA extraction from fibroblasts and ABCA1 cDNA
analysis
RNA was extracted using Eurozol (EuroClone; Celbio,
Milan, Italy) and retrotranscribed to cDNA using Super-
Script III (Invitrogen, Carlsbad, CA, USA), following the
manufacturer’s instructions. To study the transcript of
the mutant ABCA1 allele found in the proband (harboring
a deletion of exons 32, 33 and 34) the cDNA was ampli-
fied using a forward primer (5′-TGCTGCCTGTGTGTC
CCCCA-3′) complementary to exon 31 and a reverse
primer (5-GGTTGGCCCGGAGAATGGCA -3′) com-
plementary to exon 35, at the following amplification
conditions: 95°C for 2 min and 95°C for 30 sec/ 63.4°C for
30 sec/ 72°C for 50 sec for 29 cycles followed by an exten-
sion at 72°C for 5 minutes. PCR products were separated
on 4% agarose gel electrophoresis and sequenced [16].
Ultrastructural analysis of the skin biopsy
A tissue sample of 1 mm3 was fixed in 2.5% glutaral-
deide in 0.1 M cacodylate buffer for 4 hours at +4°C.
Fixed tissue was then washed with cacodylate buffer
0.15 M and then postfixed with 1% osmium tetroxide in
cacodylate buffer for 1 hour at +4°C. Tissue was dehy-
drated and embedded in Epon resin. Ultrathin sections
of 70 nm were stained with uranyl acetate and Reynold′s
lead citrate and examined with a Morgagni 286 trans-
mission electron microscope (FEI Company).
Case report
A 58 years old Caucasian female diagnosed with NPC
disease was referred to the Regional Coordinator Centre
for Rare Disease of Udine (RCCRD) in 2010. Her latest
medical history (previous 2 years) had been character-
ized by progressive neurological symptoms: pain and
hyposthenia of the left inferior leg followed by pain and
hyposthenia of the left arm, psychomotor impairment,
ataxic gait, tongue enlargement, dysarthria and dysphagia.
Her medical history included mild thrombocytopenia and
splenomegaly since the age of 32 years, dorsal skin itching
nodular lesions resembling prurigo nodularis since the age
of 40 years, and chronic lymphedema of the left leg since
the age of 43 years. Electromyography (EMG) of the legs
showed bilateral demyelinating motor neuropathy; brain
magnetic resonance imaging (MRI) was negative. Haem-
atological parameters showed the presence of pancyto-
penia (haemoglobin 10.2 g/dl, leukocytes 3700/ul, platelet
109000/ul), a bone marrow biopsy evidenced foam cells,
interpreted as a lysosomal storage disorder. On the ba-
sis of clinical and histological data a diagnosis of NPC
was made and therapy with miglustat (300 mg/day) was
commenced.
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symptoms, tongue enlargement, and left leg lymphede-
ma was observed as well as a marked improvement of
the skin lesions.
When the patient was for the first time admitted to
RCCRD (after 6 months of miglustat therapy), her neu-
rological examination was negative, skin lesions were
very mild and both tonsils were normal in size and color.
The EMG of upper and lower limbs was normal.
Specific diagnostic exams for NPC were then per-
formed. Filipin test showed mild intracellular storage of
unesterified cholesterol in cultured fibroblasts. However,
no mutations were found in the NPC1 or NPC2 genes.
Lipid profiling showed the presence of severe hypo-
cholesterolemia, total cholesterol 60 mg/dl (n.v. 130-
200 mg/dl), very low levels of HDL-cholesterol, 2 mg/dl
(n.v. 45-65 mg/dl) and apoAI, 5.19 mg/dl (n.v. 110-
170 mg/dl) and hypertrigliceridemia, 448 mg/dl (n.v. 40-
150 mg/dl). This profile was strongly suggestive for aFigure 1 Genetic analysis of the ABCA1 gene. A PCR amplification of th
# Mo.4 The figure shows the agarose gel electrophoresis of the PCR fragm
(lane 2) respectively. Molecular size markers are shown in lane 3. The size o
B Deletion of exon 32-34 of ABCA1 gene found in patient #Mo-4. The uppe
Alu Sx in intron 31 and Alu Sq2 sequences in intron 34 are involved in the
the nucleotide sequence of the genomic breakpoint indicating that the 3′
nucleotide sequence is identical in the two introns and cannot be assigneddiagnosis of TD, which was confirmed by molecular
analysis.
When PCR analysis of ABCA1 gene was performed, all
exons could be amplified and sequenced with the excep-
tion of exons 32, 33 and 34. This observation suggested
that the patient might be homozygous for a deletion of
these exons. To test this hypothesis the genomic region
spanning from intron 30 to intron 35 was amplified.
This amplification generated a ~6 kb fragment from
control DNA as opposed to a ~ 2.5 kb fragment from
the patient’s DNA, thus indicating that the patient was
homozygous for a novel ~3.5 kb deletion (Figure 1A). By
using a set of specific nucleotide primers the deletion
breakpoint (i.e. the junction between intron 31 and
intron 34) was characterized. The deletion was gener-
ated by a recombination between two Alu sequences
(Alu-SX in intron 31 and Alu-SQ2 in intron 34 re-
spectively) (Figure 1B). At the genomic level the mu-
tation was designated as c.4464-486_4698 + 382 Dele ABCA1 gene region spanning from exon 31 to exon 35 in patient
ents obtained in a control subject (lane 1) and in the proband #Mo-4
f the band seen in lane 2 is consistent with a deletion of ~ 3.5 Kb.
r panel shows Alu sequences located in intron 31 and intron 34. The
recombination event resulting in the deletion. The lower panel shows
half of intron 31 is followed by the 5′ half of intron 34. The boxed
to either of them.
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of the cDNA region spanning from exons 31 to exon 35,
revealed that the genomic deletion lead to the exclusion
of exons 32, 33 and 34 from the mature mRNA, with
no disruption of the reading frame (Additional file 1:
Figure S1). The predicted translation product of this
abnormal mRNA would be a protein with an in frame
deletion of 77 amino acids (from residue 1489 to resi-
due 1566 of ABCA1 protein) (p.R1489_K1566del). As
shown in Figure 2, cholesterol efflux was negligible in
the patient’s fibroblasts, either under basal conditions or
after stimulation of ABCA1 expression with 9-cis-retinoic
acid and 22-hydroxycholesterol. Based on these results,
the diagnosis of NPC was ruled out substituted with that
of TD. Miglustat treatment was then interrupted. Fur-
ther examinations were conducted to assess possible TD
complications: the echocolor Doppler of carotid arteries
showed a 3 mm thick atherosclerotic plaque in the left
common carotid trunk without hemodynamic signifi-
cance, the brain angio-MRI was normal. Mild corneal opa-
city was present at slit lamp examination.
Seven months after miglustat discontinuation skin le-
sions (Figure 3A) worsened, and the patient complained
about reduced ability to focus attention, memory defects
and slower thought processes. Skin biopsy of one dorsal
nodular lesion was performed. Electron microscopy exa-
mination showed a lipid accumulation in Schwann cells
of cutaneous nerves (Figure 4A and B).
These observations prompted us to hypothesize a cor-
relation between miglustat therapy and the patient’s clin-
ical improvement. Thus the therapy was restarted and
continued for another 6 months.Figure 2 3H-cholesterol efflux to Apo A-I in cultured skin fibroblasts.
presence of 22-hydroxycholesterol and 9-cis-retinoic acid (22OH/cRA) (blac
#Mo-4: patient with the clinical diagnosis of Tangier Disease described in th
previous study [4].During this period the patient showed a progressive
amelioration of the skin lesions (Figure 3B) and a sub-
jective improvement of general and mental wellbeing,
with less fatigue and faster thought processes. No sub-
stantial improvements were noted in spleen volume, blood
counts and plasma levels of HDL, ApoA1, total choles-
terol and triglycerides.
Discussion
This report describes for the first time the remission of
neurocutaneous and neurological manifestations during
miglustat treatment in an atypical patient with TD, ini-
tially misdiagnosed as NPC disease.
The patient had an unusual disease presentation with
peripheral motor neuropathy concomitant with central
nervous system symptoms, including psychomotor im-
pairment, disabling ataxia, dysarthria and dysphagia. In-
terestingly, a first case of TD with predominant central
nervous system findings, including dysarthria and ataxic
gait (raised together with peripheral neuropathy), has
been recently described in a 38-year-old female. The pa-
tient was found to be homozygous for a mutation at the
3′ acceptor splice site of intron 32 of the ABCA1 gene
[5]. Although the effect of this mutation on mRNA spli-
cing has not been analyzed, it is likely that it causes the
skipping of exon 33. If that were the case, the encoded
protein would have an in frame deletion of 31 amino
acids. Similarly, the abnormal ABCA1 protein of the pa-
tient described here has an in frame deletion of 77
amino acids (encoded by exons 32-34), indicating that
the same domain of ABCA1 is disrupted in the two pa-
tients. Phenotypically, both patients had neurologicalCells were incubated under basal conditions (white bars) and in the
k bars) to stimulate ABCA1 gene expression. Ctrl: healthy control cells;
is study; TDPK: control patient with Tangier Disease reported in a
Figure 3 Improvement of dorsal skin lesions after miglustat treatment. Images showing the improvement on miglustat treatment of the
dorsal skin lesions resembling prurigo nodularis of the patient with Tangier Disease described in this study. Pictures taken A after 7 months of
miglustat discontinuation; B after 6 months of miglustat treatment.
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generally considered a hallmark of TD. Taken together,
these results indicate that the diagnosis of TD should
be considered in patients showing neurological symp-
toms and very low HDL, even in the presence of nor-
mal tonsils.
A further unusual feature of the patient described here
was the dorsal skin disease, resembling prurigo nodu-
laris. Prurigo nodularis is an uncommon skin disease
characterized by itchy nodules that can appear on any
part of the body, usually beginning on the limbs. The
itching and the consequent scratching of theses lesions
may have a very negative impact on quality of life, and
its treatment is usually challenging. The pathogenesis of
these lesions remains incompletely understood. How-
ever, recent data suggest a neuropathic origin [17]. The
finding of enlarged Schwann cells with lipid accumula-
tion in the cutaneous nerves of the patient’s skin lesions
suggests a direct link between prurigo nodularis and TD.
It is likely that the alteration of peripheral cutaneous
nerves leads to neurocutaneous manifestations. The pres-
ence of lipid accumulation in Schwann cells of patients
with TD has been correlated previously with the periph-
eral neuropathy associated with this disease [18,19].Figure 4 Lipid accumulation in Schwann cells of cutaneous nerves. El
cytoplasmic lipid droplets (2800 ×) and B well-formed redundant continuoNeurologic manifestations of TD are considered as peri-
odically relapsing-remitting [19]. Nevertheless, our patient,
who underwent two different periods of 6-month treat-
ment with miglustat, showed an improvement of neuro-
logical symptoms and skin lesions only when she was on
treatment and relapses when the drug was discontinued.
Several studies have described a link between ABCA1
expression/function and the NPC pathway. ABCA1 is
the rate-limiting step in the initial formation of plasma
HDL, transferring cellular phospholipids and cholesterol
to ApoAI [20]. It is well established that ABCA1 is not
only localized on the cell surface, but also in late endo-
somes/lysosomes [21], suggesting that it plays a role in
mobilizing lipids from intracellular vesicles to the extra-
cellular ApoAI. NPC1 and NPC2, the proteins defective
in NPC disease, are also located in late endosomes/lyso-
somes but not at the cell surface, their function being
confined to intracellular lipid trafficking [22]. Further-
more, fibroblasts from TD and NPC patients share sev-
eral common features: both accumulate cholesterol and
sphingomyelin in late endocytic vesicles [7] and both show
impaired ABCA1 dependent lipid efflux to ApoAI [6].
These findings suggest interdependence between the NPC
disease pathway and ABCA1 function.ectron microphotographs showing A Schwann cells with accumulating
us basal lamina at the cell surface. (3500 ×).
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leads to the accumulation of several lipids, in particular,
GSL are the main species accumulating in the central
nervous system [10]. Since miglustat (an inhibitor of GSL
synthesis) ameliorated some of the clinical manifestations
of TD in this case report, it is tempting to hypothesize
that, similarly to NPC, TD patients may accumulate intra-
cellular GSL or their derivatives, which could be impli-
cated in the pathogenesis of the disease. Further studies to
investigate this hypothesis are currently in progress.
It is also worth noting that miglustat showed a positive
effect on HDL metabolism in a different lysosomal dis-
order, Gaucher disease. In fact, patients with Gaucher
disease treated with miglustat showed significantly in-
creased HDL and ApoAI levels [23]. The mechanism be-
hind this effect still needs to be further investigated.
However, miglustat did not affect the lipid profile in our
TD patient, suggesting that it was not be able to restore
the severe defect in cholesterol efflux due to the absence
of a functional ABCA1 identified in this patient.
Conclusions
Although the apparent improvement of neurological
manifestations upon treatment of miglustat in a single
patient cannot be taken as an indication of its effective-
ness in TD, our data suggest that GSL could play a role
in the pathogenesis of this disease, and that miglustat
may represent a possible novel therapeutic approach for
TD. The mechanisms by which miglustat ameliorates at
least some clinical manifestations of Tangier disease merit
further investigations.
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